Safety and effectiveness of tirzepatide during Ramadan fasting: Real‐world evidence from patients with type 2 diabetes in Bangladesh
Main finding · HbA1cResult — go to the resultMean change −1.1 %Authors' conclusion
Tirzepatide demonstrated significant improvements in glycaemic control and body weight, with good tolerability, among patients with type 2 diabetes in Bangladesh who fasted during Ramadan.
Study context
- Population
- Adults with T2D in Bangladesh intending to fast during Ramadan; mean age 40.7 ± 12.8 years, 69.7% female, 86.7% obese
- Participants
- 109 adults
- Exposure
- Before vs after Ramadan on tirzepatide
- Tirzepatiden = 109
- Outcome
- HbA1c
- Follow-up
- 2-6 weeks before Ramadan to 2-6 weeks after Ramadan
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
Mean change
−1.1 %
P < 0.001
- Mean HbA1c before Ramadan
- 7.6%
- Mean HbA1c after Ramadan
- 6.5%
Observational data: associations, not effects.
Further findings
FPG
- Significant reduction in FPG
- −2 mmol/L (p <0.001)
2-h postprandial glucose
- Significant reduction in 2-h postprandial glucose
- - 3.8 mmol/L (p <0.001)
Body weight
- Mean body weight reduction (SD 3.9)
- 5.3 kg (6.3% of baseline; p <0.001)
Safety
Adverse events · 2-6 weeks after Ramadan
- Mild gastrointestinal events
- ≈12% of participants
- No hypoglycemia reported
Original publication
Safety and effectiveness of tirzepatide during Ramadan fasting: Real‐world evidence from patients with type 2 diabetes in Bangladesh. Diabetes Obes Metab. Published 4 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →